-
Je něco špatně v tomto záznamu ?
International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia
O. Hrusak, V. de Haas, J. Stancikova, B. Vakrmanova, I. Janotova, E. Mejstrikova, V. Capek, J. Trka, M. Zaliova, A. Luks, K. Bleckmann, A. Möricke, J. Irving, B. Konatkowska, TB. Alexander, H. Inaba, K. Schmiegelow, S. Stokley, Z. Zemanova, AV....
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, multicentrická studie, práce podpořená grantem
Grantová podpora
NV15-28525A
MZ0
CEP - Centrální evidence projektů
Digitální knihovna NLK
Plný text - Článek
Zdroj
Freely Accessible Science Journals od 1946 do Před 1 rokem
Open Access Digital Library od 1946-01-01
Open Access Digital Library od 1946-01-01
Elsevier Open Access Journals od 1946-01-01 do 2023-06-22
ROAD: Directory of Open Access Scholarly Resources
Elsevier Open Archive Journals od 1946 do Před 1 rokem
Odkazy
PubMed
29720486
DOI
10.1182/blood-2017-12-821363
Knihovny.cz E-zdroje
- MeSH
- akutní bifenotypická leukemie diagnóza etiologie terapie MeSH
- biologické markery MeSH
- dítě MeSH
- kojenec MeSH
- kombinovaná terapie MeSH
- lidé MeSH
- management nemoci MeSH
- mladiství MeSH
- náchylnost k nemoci MeSH
- nádorové biomarkery MeSH
- novorozenec MeSH
- předškolní dítě MeSH
- prognóza MeSH
- proporcionální rizikové modely MeSH
- výsledek terapie MeSH
- Check Tag
- dítě MeSH
- kojenec MeSH
- lidé MeSH
- mladiství MeSH
- mužské pohlaví MeSH
- novorozenec MeSH
- předškolní dítě MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
Despite attempts to improve the definitions of ambiguous lineage leukemia (ALAL) during the last 2 decades, general therapy recommendations are missing. Herein, we report a large cohort of children with ALAL and propose a treatment strategy. A retrospective multinational study (International Berlin-Frankfurt-Münster Study of Leukemias of Ambiguous Lineage [iBFM-AMBI2012]) of 233 cases of pediatric ALAL patients is presented. Survival statistics were used to compare the prognosis of subsets and types of treatment. Five-year event-free survival (EFS) of patients with acute lymphoblastic leukemia (ALL)-type primary therapy (80% ± 4%) was superior to that of children who received acute myeloid leukemia (AML)-type or combined-type treatment (36% ± 7.2% and 50% ± 12%, respectively). When ALL- or AML-specific gene fusions were excluded, 5-year EFS of CD19+ leukemia was 83% ± 5.3% on ALL-type primary treatment compared with 0% ± 0% and 28% ± 14% on AML-type and combined-type primary treatment, respectively. Superiority of ALL-type treatment was documented in single-population mixed phenotype ALAL (using World Health Organization and/or European Group for Immunophenotyping of Leukemia definitions) and bilineal ALAL. Treatment with ALL-type protocols is recommended for the majority of pediatric patients with ALAL, including cases with CD19+ ALAL. AML-type treatment is preferred in a minority of ALAL cases with CD19- and no other lymphoid features. No overall benefit of transplantation was documented, and it could be introduced in some patients with a poor response to treatment. As no clear indicator was found for a change in treatment type, this is to be considered only in cases with ≥5% blasts after remission induction. The results provide a basis for a prospective trial.
1st Department of Pediatrics University of Athens Athens Greece
Bioinformatics Centre 2nd Faculty of Medicine Charles University Prague Czech Republic
Comenius University Children's Hospital Bratislava Slovakia
Department of Oncology St Jude Children's Research Hospital Memphis TN
Department of Pathology St Jude Children's Research Hospital Memphis TN
Department of Pediatric Hematology Oncology Aghia Sophia Children's Hospital Athens Greece
Helios Klinikum Berlin Buch Berlin Germany
Hematology and Oncology Hospital Nacional de Pediatría Prof Dr J P Garrahan Buenos Aires Argentina
Immunology and Rheumatology and
Institute of Medicine Faculty of Medicine University of Copenhagen Copenhagen Denmark
Northern Institute for Cancer Research Newcastle University Newcastle upon Tyne United Kingdom
Nottingham University Hospitals NHS Trust Nottingham United Kingdom
Pediatric Hematology and Oncology University Children's Hospital Essen Essen Germany
Pediatric Hematology Oncology Baylor College of Medicine Houston TX
Pediatric Hematology Oncology Schneider Children's Medical Center Petah Tikva Israel
Pediatrics Department Faculty of Medicine Federal University of Rio de Janeiro Rio de Janeiro Brazil
Sackler Faculty of Medicine Tel Aviv University Tel Aviv Israel
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19035270
- 003
- CZ-PrNML
- 005
- 20201022094940.0
- 007
- ta
- 008
- 191007s2018 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1182/blood-2017-12-821363 $2 doi
- 035 __
- $a (PubMed)29720486
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Hrusak, Ondrej $u Childhood Leukemia Investigation Prague, Prague, Czech Republic. Department of Pediatric Hematology/Oncology, Charles University, Second Faculty of Medicine, Hospital Motol, Prague, Czech Republic.
- 245 10
- $a International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia / $c O. Hrusak, V. de Haas, J. Stancikova, B. Vakrmanova, I. Janotova, E. Mejstrikova, V. Capek, J. Trka, M. Zaliova, A. Luks, K. Bleckmann, A. Möricke, J. Irving, B. Konatkowska, TB. Alexander, H. Inaba, K. Schmiegelow, S. Stokley, Z. Zemanova, AV. Moorman, JG. Rossi, MS. Felice, L. Dalla-Pozza, J. Morales, M. Dworzak, B. Buldini, G. Basso, M. Campbell, ME. Cabrera, N. Marinov, S. Elitzur, S. Izraeli, D. Luria, T. Feuerstein, A. Kolenova, P. Svec, O. Kreminska, KR. Rabin, S. Polychronopoulou, E. da Costa, HV. Marquart, A. Kattamis, R. Ratei, D. Reinhardt, JK. Choi, M. Schrappe, J. Stary,
- 520 9_
- $a Despite attempts to improve the definitions of ambiguous lineage leukemia (ALAL) during the last 2 decades, general therapy recommendations are missing. Herein, we report a large cohort of children with ALAL and propose a treatment strategy. A retrospective multinational study (International Berlin-Frankfurt-Münster Study of Leukemias of Ambiguous Lineage [iBFM-AMBI2012]) of 233 cases of pediatric ALAL patients is presented. Survival statistics were used to compare the prognosis of subsets and types of treatment. Five-year event-free survival (EFS) of patients with acute lymphoblastic leukemia (ALL)-type primary therapy (80% ± 4%) was superior to that of children who received acute myeloid leukemia (AML)-type or combined-type treatment (36% ± 7.2% and 50% ± 12%, respectively). When ALL- or AML-specific gene fusions were excluded, 5-year EFS of CD19+ leukemia was 83% ± 5.3% on ALL-type primary treatment compared with 0% ± 0% and 28% ± 14% on AML-type and combined-type primary treatment, respectively. Superiority of ALL-type treatment was documented in single-population mixed phenotype ALAL (using World Health Organization and/or European Group for Immunophenotyping of Leukemia definitions) and bilineal ALAL. Treatment with ALL-type protocols is recommended for the majority of pediatric patients with ALAL, including cases with CD19+ ALAL. AML-type treatment is preferred in a minority of ALAL cases with CD19- and no other lymphoid features. No overall benefit of transplantation was documented, and it could be introduced in some patients with a poor response to treatment. As no clear indicator was found for a change in treatment type, this is to be considered only in cases with ≥5% blasts after remission induction. The results provide a basis for a prospective trial.
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a biologické markery $7 D015415
- 650 _2
- $a nádorové biomarkery $7 D014408
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a předškolní dítě $7 D002675
- 650 _2
- $a kombinovaná terapie $7 D003131
- 650 _2
- $a management nemoci $7 D019468
- 650 _2
- $a náchylnost k nemoci $7 D004198
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a kojenec $7 D007223
- 650 _2
- $a novorozenec $7 D007231
- 650 _2
- $a akutní bifenotypická leukemie $x diagnóza $x etiologie $x terapie $7 D015456
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a proporcionální rizikové modely $7 D016016
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a de Haas, Valerie $u Dutch Childhood Oncology Group, The Hague, The Netherlands. Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
- 700 1_
- $a Stancikova, Jitka $u Childhood Leukemia Investigation Prague, Prague, Czech Republic. Department of Pediatric Hematology/Oncology, Charles University, Second Faculty of Medicine, Hospital Motol, Prague, Czech Republic.
- 700 1_
- $a Vakrmanova, Barbora $u Childhood Leukemia Investigation Prague, Prague, Czech Republic. Department of Pediatric Hematology/Oncology, Charles University, Second Faculty of Medicine, Hospital Motol, Prague, Czech Republic.
- 700 1_
- $a Janotova, Iveta $u Department of Pediatric Hematology/Oncology, Charles University, Second Faculty of Medicine, Hospital Motol, Prague, Czech Republic.
- 700 1_
- $a Mejstrikova, Ester $u Childhood Leukemia Investigation Prague, Prague, Czech Republic. Department of Pediatric Hematology/Oncology, Charles University, Second Faculty of Medicine, Hospital Motol, Prague, Czech Republic.
- 700 1_
- $a Capek, Vaclav $u Bioinformatics Centre, Second Faculty of Medicine, Charles University, Prague, Czech Republic.
- 700 1_
- $a Trka, Jan $u Childhood Leukemia Investigation Prague, Prague, Czech Republic. Department of Pediatric Hematology/Oncology, Charles University, Second Faculty of Medicine, Hospital Motol, Prague, Czech Republic.
- 700 1_
- $a Zaliova, Marketa $u Childhood Leukemia Investigation Prague, Prague, Czech Republic. Department of Pediatric Hematology/Oncology, Charles University, Second Faculty of Medicine, Hospital Motol, Prague, Czech Republic.
- 700 1_
- $a Luks, Ales $u Department of Pediatric Hematology/Oncology, Charles University, Second Faculty of Medicine, Hospital Motol, Prague, Czech Republic.
- 700 1_
- $a Bleckmann, Kirsten $u University Medical Center, Christian Albrechts University Kiel, Kiel, Germany. Department of Pediatrics, University Medical Center Schleswig Holstein, Campus Kiel, Kiel, Germany.
- 700 1_
- $a Möricke, Anja $u University Medical Center, Christian Albrechts University Kiel, Kiel, Germany. Department of Pediatrics, University Medical Center Schleswig Holstein, Campus Kiel, Kiel, Germany.
- 700 1_
- $a Irving, Julie $u Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom.
- 700 1_
- $a Konatkowska, Benigna $u Department of Pediatric Hematology, Oncology and Transplantology, University of Medical Sciences, Poznan, Poland.
- 700 1_
- $a Alexander, Thomas B $u Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN.
- 700 1_
- $a Inaba, Hiroto $u Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN.
- 700 1_
- $a Schmiegelow, Kjeld $u Nordic Society for Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, The Juliane Marie Centre, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. Institute of Medicine, Faculty of Medicine, University of Copenhagen, Copenhagen, Denmark.
- 700 1_
- $a Stokley, Simone $u Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom.
- 700 1_
- $a Zemanova, Zuzana $u Center of Oncocytogenetics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic.
- 700 1_
- $a Moorman, Anthony V $u Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom.
- 700 1_
- $a Rossi, Jorge Gabriel $u Immunology and Rheumatology and.
- 700 1_
- $a Felice, Maria Sara $u Hematology and Oncology, Hospital Nacional de Pediatría Prof. Dr. J. P. Garrahan, Buenos Aires, Argentina.
- 700 1_
- $a Dalla-Pozza, Luciano $u Sydney Children's Hospital Network, Westmead, NSW, Australia.
- 700 1_
- $a Morales, Jessa $u Sydney Children's Hospital Network, Westmead, NSW, Australia.
- 700 1_
- $a Dworzak, Michael $u Department of Pediatrics, Medical University of Vienna, St. Anna Children's Hospital and Children's Cancer Research Institute, Vienna, Austria.
- 700 1_
- $a Buldini, Barbara $u Laboratory of Pediatric Oncohematology, Department of Woman's and Child's Health, University of Padova, Padova, Italy.
- 700 1_
- $a Basso, Giuseppe $u Laboratory of Pediatric Oncohematology, Department of Woman's and Child's Health, University of Padova, Padova, Italy.
- 700 1_
- $a Campbell, Myriam $u National Program for Antineoplastic Drugs for Children (PINDA), Chilean National Pediatric Oncology Group, Hospital Roberto del Rio/Universidad de Chile, Santiago, Chile. Hospital del Salvador, Universidad de Chile, Santiago, Chile.
- 700 1_
- $a Cabrera, Maria Elena $u National Program for Antineoplastic Drugs for Children (PINDA), Chilean National Pediatric Oncology Group, Hospital Roberto del Rio/Universidad de Chile, Santiago, Chile. Hospital del Salvador, Universidad de Chile, Santiago, Chile.
- 700 1_
- $a Marinov, Neda $u National Program for Antineoplastic Drugs for Children (PINDA), Chilean National Pediatric Oncology Group, Hospital Roberto del Rio/Universidad de Chile, Santiago, Chile. Hospital del Salvador, Universidad de Chile, Santiago, Chile.
- 700 1_
- $a Elitzur, Sarah $u Pediatric Hematology Oncology, Schneider Children's Medical Center, Petah-Tikva, Israel.
- 700 1_
- $a Izraeli, Shai $u Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
- 700 1_
- $a Luria, Drorit $u Pediatric Hematology Oncology, Schneider Children's Medical Center, Petah-Tikva, Israel.
- 700 1_
- $a Feuerstein, Tamar $u Pediatric Hematology Oncology, Schneider Children's Medical Center, Petah-Tikva, Israel.
- 700 1_
- $a Kolenova, Alexandra $u Comenius University Children's Hospital, Bratislava, Slovakia.
- 700 1_
- $a Svec, Peter $u Comenius University Children's Hospital, Bratislava, Slovakia.
- 700 1_
- $a Kreminska, Olena $u Center of Children's Oncohematology and BMT, National Children's Specialized Hospital "OHMATDYT," Kiev, Ukraine.
- 700 1_
- $a Rabin, Karen R $u Pediatric Hematology/Oncology, Baylor College of Medicine, Houston, TX.
- 700 1_
- $a Polychronopoulou, Sophia $u Department of Pediatric Hematology/Oncology, "Aghia Sophia" Children's Hospital, Athens, Greece.
- 700 1_
- $a da Costa, Elaine $u Pediatrics Department, Faculty of Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
- 700 1_
- $a Marquart, Hanne Vibeke $u Institute of Medicine, Faculty of Medicine, University of Copenhagen, Copenhagen, Denmark.
- 700 1_
- $a Kattamis, Antonis $u First Department of Pediatrics, University of Athens, Athens, Greece.
- 700 1_
- $a Ratei, Richard $u Helios Klinikum Berlin Buch, Berlin, Germany.
- 700 1_
- $a Reinhardt, Dirk $u Pediatric Hematology and Oncology, University Children's Hospital Essen, Essen, Germany; and.
- 700 1_
- $a Choi, John K $u Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN.
- 700 1_
- $a Schrappe, Martin $u University Medical Center, Christian Albrechts University Kiel, Kiel, Germany. Department of Pediatrics, University Medical Center Schleswig Holstein, Campus Kiel, Kiel, Germany.
- 700 1_
- $a Stary, Jan $u Department of Pediatric Hematology/Oncology, Charles University, Second Faculty of Medicine, Hospital Motol, Prague, Czech Republic.
- 773 0_
- $w MED00000807 $t Blood $x 1528-0020 $g Roč. 132, č. 3 (2018), s. 264-276
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29720486 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20191007 $b ABA008
- 991 __
- $a 20201022094937 $b ABA008
- 999 __
- $a ok $b bmc $g 1451930 $s 1073820
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 132 $c 3 $d 264-276 $e 20180502 $i 1528-0020 $m Blood $n Blood $x MED00000807
- GRA __
- $a NV15-28525A $p MZ0
- LZP __
- $a Pubmed-20191007